by 149bio | Aug 8, 2023 | Announcement
Miami, FL, August 8, 2023, (AllositeTx) – 149 Bio, LLC (DBA Allosite Therapeutics), a pioneering biotechnology company, announced launch of its updated website as Allosite Therapeutics. This strategic update reflects our focus on developing innovative therapeutics...
by 149bio | Feb 23, 2023 | Press Release
Clinical asset planned to be advanced in Lupus Nephritis and other indications Program includes first-in-class integrin activator for myeloid cell integrin CD11b CD11b activation reduces myeloid overactivation and tissue damage Target validated in multiple auto-immune...
by 149bio | Oct 10, 2022 | Press Release
Podocytes are lost in urine in many kidney diseases and its integrin receptor α3β1 keeps them in place The company has identified novel allosteric agonist antibodies against α3β1 to anchor podocytes Integrin α3β1 specific agonist antibodies expected to move to...
Recent Comments